Steps to protect your liver

Maintaining a healthy lifestyle and getting the Hepatitis B vaccine is the most effective way of preventing liver cancer, writes KASMIAH MUSTAPHA. IT may not have received as much attention as other forms of cancer, but in reality, liver cancer is the most common cancer in the world. It is also the third leading cause of cancer-related deaths worldwide.

Making it even more deadly are the two types of liver cancer — primary and secondary. Primary liver cancer is defined as cancer that begins in liver cells — called hepatocytes. This type of cancer is called hepatocellular carcinoma (HCC), which accounts for 90 per cent of liver cancer cases.

Secondary liver cancer is the result of the mutation of the cells from another type of cancer which spreads to the liver.

HCC is caused by several factors which include chronic infection of hepatitis B and/or hepatitic C virus, cirrhosis which is scar tissues of the liver, alcohol abuse, long-term exposure to alfatoxins which is produced by many species of fungus that can be found in tree nuts, peanuts and other oilseed, smoking, long-term use of anabolic steroids and obesity.

Often HCC has no symptoms until the cancer is at an advanced stage making early treatment almost impossible.

Symptoms usually include fatigue, pain on the right side of the upper abdomen or around the right shoulder blade, nausea, loss of appetite, feeling full after a small meal, unexplained weight loss and jaundice.

Consultant clinical oncologist Dr Chong Kwang Jeat says the prognosis for HCC is never good with the survival rate of less than a year. This is largely due to the fact that the symptoms are presented at an advanced stage and there are very few treatment options for the patients.

“Liver cancer is under-reported due to lack of awareness and there is certainly a high medical need for an early and reliable diagnosis as well as for an effective life-prolonging treatment,” he added.

In Malaysia, liver cancer is the 10th most common cancer among men and the 15th most common cancer among women.

In 2003, there were 530 cases of HCC reported in Malaysia. Ninety per cent of HCC is cause by hepatitis B, followed by hepatitis C and alcohol.

However, while it may be impossible to prevent secondary liver cancer, there are possibilities of reducing the risks from HCC by taking steps to protect your liver.

Those in the high risks group — namely those with chronic hepatitis B, C and drink alcohol — should go for screening often as early detection have the potential to cure the disease.

“The most effective way of preventing liver cancer is to get vaccination from hepatitis B. The vaccination will provide protection from the infectious disease and at the same time protect your liver from HCC.”

According to the World Health Organisation, hepatitis B vaccine has an outstanding record of safety and effectiveness. Since 1982, over one billion doses of hepatitis B vaccine have been used worldwide. Studies have shown that the vaccine is 95 per cent effective in preventing children and adults from developing chronic infection if they have not yet been infected.

Dr Chong says treatment for liver cancer will depend on the stage of the disease. If it is caught in the early stage, surgery to remove the cancerous growth will be done. However only about 15 per cent of patients can be operated on.

“Treatments include surgery, radiation therapy, chemotherapy, percutaneous ethanol injection and targeted therapy.”

Meanwhile, Professor Dr Peter Galle, Department of Internal Medicine director at the University of Mainz in Germany, says surgery and chemotherapy are used to treat liver cancer that is diagnosed in the early stage, when the tumour is confined to a small area of the liver.

“Unfortunately liver cancer is a devastating disease that is diagnosed too late, too often. This is because there are no symptoms in the early stages of the disease.”

Bayer Schering Pharma had recently launched sorafenib as the oral targeted therapy for the treatment of liver cancer. Sorafenib was approved and launched in Malaysia for the treatment of kidney cancer last year. Based on clinical trials, it is found that sorafenib improves patient’s survival rate by 44 per cent.
__________
source: NST Online, http://www.nst.com

More Treatment & Detox Articles

Working hard, drinking harder

When does a glass or two at the end of the day spill over into high-functioning alcoholism? After work every day you either go to the pub or return home to crack open a bottle of wine. Twice a week you might drink so much alcohol that you suffer memory loss. You spend much of….

Warning signs of teen drug abuse

Drug abuse in teens, is not a new problem for our modernized society. The drug abuse has widely spread and almost every part of the world is affected by this fatal addiction. The drug abuse has proved to be a great threat for the upcoming younger generation. Since, teen drug abuse constitutes of the larger….

Stressed Diggers turning to alcohol on return from front line

ALCOHOL has become the treatment of choice for an unfortunate number of Australian troops left traumatised by their service in East Timor, Afghanistan and Iraq. Taxpayers are now funding rehabilitation and sometimes compensation for their addiction, not to mention attempts to break it, as troops return from mostly dry operations to deal with their problems….

Addiction Advances Haven’t Made AA Obsolete

Although they approach the challenge of addiction differently from scientists, 12-step programs still have a therapeutic role in helping human beings. Alcoholics Anonymous may have pioneered the concept of alcoholism as a disease, but will scientific research that proves the point eventually make AA obsolete? Studies that reveal brain and genetic links to addiction seem….

Housing Homeless Alcoholics Cuts Public Costs, Alcohol Use

Permanent housing for homeless patients with ongoing drinking problems can help reduce medical and social costs and lower alcohol consumption, researchers here said. In one year, the so-called “Housing First” program cut costs from about $8 million to $4 million across the study sample, Mary E. Larimer, Ph.D., of the University of Washington, and colleagues….